NeuroScientific Biopharmaceuticals (NSB) Company presentation summary

Financial position and capital structure

• Market capitalization of $43.2M and $6.4M in cash as of December 2025.

• Share price at A$0.13 with 332.6 million ordinary shares and 57.1 million performance shares.

• 48.25 million options outstanding.

Leadership and advisory strength

• Leadership team includes experienced executives from major pharma and biotech firms.

• Scientific Advisory Board features experts in haematology, transplantation, and respiratory medicine.

• Recent appointments include a new CEO and Chief Medical Officer.

Technology and clinical progress

• StemSmart™ is a patented MSC technology with a strong safety profile and 78% response in refractory Crohn's trial.

• Special Access Program for Fistulising Crohn's Disease showed clinical response in three out of four patients.

• Manufacturing secured through partnership with GMP-licensed Q-Gen Cell Therapeutics.